CVOTs: What did the endocrinologist learn?

Area of Science:

• Cardiology
• Endocrinology
• Nephrology

Background:

• Cardiovascular outcome trials (CVOTs) have evaluated new glucose-lowering drugs (GLD) for type 2 diabetes mellitus (T2DM).
• These trials provide crucial data on the long-term safety and metabolic effects of these medications.

Purpose of the Study:

• To summarize the findings of recent CVOTs regarding GLD in T2DM patients.
• To highlight the cardiovascular and renal benefits of specific GLD classes.
• To inform clinical decision-making and guideline recommendations for T2DM management.

Main Methods:

• Analysis of recent Cardiovascular Outcome Trials (CVOTs) for glucose-lowering drugs (GLD).
• Evaluation of drug effects on cardiovascular events, heart failure hospitalizations, mortality, and microvascular complications, including renal outcomes.
• Assessment of drug-specific mechanisms of action, distinguishing between atherosclerosis-related and heart failure-related benefits.

Main Results:

• GLD can reduce cardiovascular complications (ischemic events, heart failure hospitalization, mortality) and microvascular complications (renal outcomes) in T2DM patients.
• Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) primarily reduce atherosclerosis-related events.
• Sodium-glucose cotransporter-2 inhibitors (SGLT-2is) primarily reduce heart failure-related events.
• Mechanisms beyond glucose control are implicated in these benefits.

Conclusions:

• Current evidence supports incorporating GLD with proven cardiovascular and renal benefits into T2DM treatment guidelines (EASD-ADA, ESC/EASD).
• Treatment decisions should prioritize cardiovascular and renal risk assessment for optimal GLD selection.
• Enhanced collaboration between endocrinologists, cardiologists, nephrologists, and primary care practitioners is essential for effective T2DM management.